Spots Global Cancer Trial Database for A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer
Official Title: A Study Evaluating Safety and Efficacy of Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Adenocarcinoma
Study ID: NCT01025570
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to find out the effects, good and/or bad, of the combination of two drugs, gemcitabine and bosutinib, in patients with resected pancreatic cancer and whether this combination can prevent pancreatic cancer from coming back.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
Contact Details
Name: Andrew H. Ko, MD
Affiliation: University of California, San Francisco
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
